Josep Tabernero, Director of the Vall d’Hebron Institute of Oncology (VHIO), presented data from the international phase III SUNLIGHT study during an Oral Abstract Session at this week’s American Society of Clinical Oncology’s (ASCO) 20th Annual Gastrointestinal Cancers Symposium, January 19-21, San Francisco, CA (U.S.).
Study points to practice-changing care for patients with refractory metastatic colorectal cancer
Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology (VHIO), presented data from the international phase III SUNLIGHT study during an Oral Abstract Session at this week's American Society of Clinical Oncology's (ASCO) 20th Annual Gastrointestinal Cancers Symposium, January 19-21, San Francisco, CA (U.S.).